Combination of telmisartan plus amlodipine in the treatment of hypertension: review of results

Abstract

The rate of control of hypertension remains suboptimal despite widespread educational programs and an increasing number of novel medications. The combination of drugs with different mechanisms of action has become an alternative to improve blood pressure reduction and control, enhance adherence to the treatment and reduce adverse events. Telmisartan and amlodipine in monotherapy provide effective blood pressure lowering at all clinically relevant doses, but less than 50% of stage 1 and 2 achieve the target blood pressure. This article presents most of the relevant results of combinations of telmisartan plus amlodipine, at different doses, in hypertensive patients and a post hoc analysis of subgroups including the elderly, Type 2 diabetics, those with systolic hypertension and obese patients.

Triple drug combination of telmisartan, amlodipine and hydrochlorothiazide in the treatment of essential hypertension

“…Many authors have demonstrated the superiority of telmisartan when combined with other antihypertensives like amlodipine or HCT compared to monotherapy. [11][12][13][14]. Telmisartan combinations were also better in BP reduction compared to other ARB combinations [15].…”

Early combination therapy with telmisartan plus amlodipine for rapid achievement of blood pressure goals

“…There is also evidence that a combination of the ARB, telmisartan, and the CCB, amlodipine, provides superior BP lowering compared with that of the individual monotherapies (15,16). This combination has also been demonstrated to be effective in patients at all stages of hypertension, as well as in those with added risk such as comorbid obesity, diabetes or metabolic syndrome (17)(18)(19)(20)(21)(22)(23).…”